Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM.

J Infect Dis. 2006 May 1;193(9):1223-8. Epub 2006 Mar 28.

2.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.

King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.

Vaccine. 2009 Nov 5;27(47):6589-94. doi: 10.1016/j.vaccine.2009.08.032. Epub 2009 Aug 27.

PMID:
19716456
3.

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults.

Lakey DL, Treanor JJ, Betts RF, Smith GE, Thompson J, Sannella E, Reed G, Wilkinson BE, Wright PF.

J Infect Dis. 1996 Oct;174(4):838-41.

4.

Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.

Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB.

J Infect Dis. 2006 Nov 15;194(10):1394-7. Epub 2006 Oct 6.

5.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
6.

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

Treanor JJ, Betts RF, Smith GE, Anderson EL, Hackett CS, Wilkinson BE, Belshe RB, Powers DC.

J Infect Dis. 1996 Jun;173(6):1467-70.

7.

Evaluation of the safety, reactogenicity and immunogenicity of FluBlokĀ® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.

Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM.

Vaccine. 2011 Mar 9;29(12):2272-8. doi: 10.1016/j.vaccine.2011.01.039. Epub 2011 Jan 28.

PMID:
21277410
8.

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM.

Vaccine. 2001 Feb 8;19(13-14):1732-7.

PMID:
11166898
9.

Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.

Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G.

Vaccine. 2008 Dec 2;26(51):6614-9. doi: 10.1016/j.vaccine.2008.09.078. Erratum in: Vaccine. 2010 Nov 23;28(50):8033.

PMID:
18930093
11.

Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination.

Morelon E, Pouteil Noble C, Daoud S, Cahen R, Goujon-Henry C, Weber F, Laurent PE, Kaiserlian D, Nicolas JF.

Vaccine. 2010 Oct 4;28(42):6885-90. doi: 10.1016/j.vaccine.2010.08.015. Epub 2010 Aug 13.

PMID:
20709000
12.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

13.

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.

Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM.

Vaccine. 2009 Dec 11;28(2):379-85. doi: 10.1016/j.vaccine.2009.10.037. Epub 2009 Oct 29.

PMID:
19879222
14.

Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.

Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P.

Vaccine. 2009 Dec 9;27(52):7304-12. doi: 10.1016/j.vaccine.2009.10.033. Epub 2009 Oct 20.

PMID:
19849996
15.

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.

Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.

Hum Vaccin. 2005 Jan-Feb;1(1):37-42. Epub 2005 Jan 12.

PMID:
17038827
16.

Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.

Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD; GRC28 Study Team.

Pediatr Infect Dis J. 2010 Feb;29(2):105-10. doi: 10.1097/INF.0b013e3181b84c34.

PMID:
19934787
17.

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.

Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, Wolff M, Klimov A, Levandowski R, Lambert L.

Vaccine. 2002 Jan 15;20(7-8):1099-105.

PMID:
11803070
18.

Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.

Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.

Clin Infect Dis. 2009 Apr 15;48(8):1087-95. doi: 10.1086/597401.

19.

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, Al-Ibrahim MS, Kabongo ML, Steigbigel R, Belshe RB, Kitt ER, Chu AH, Moss RB.

Vaccine. 2010 Mar 16;28(13):2565-72. doi: 10.1016/j.vaccine.2010.01.029. Epub 2010 Jan 29.

PMID:
20117262
20.

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.

Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M.

JAMA. 2007 Apr 11;297(14):1577-82.

PMID:
17426277
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk